RAYMOND JAMES & ASSOCIATES - ADAPTIMMUNE THERAPEUTICS PLC ownership

ADAPTIMMUNE THERAPEUTICS PLC's ticker is ADAP and the CUSIP is 00653A107. A total of 70 filers reported holding ADAPTIMMUNE THERAPEUTICS PLC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
RAYMOND JAMES & ASSOCIATES ownership history of ADAPTIMMUNE THERAPEUTICS PLC
ValueSharesWeighting
Q3 2023$8,088
-16.3%
10,369
-0.8%
0.00%
Q2 2023$9,665
-21.5%
10,449
-7.5%
0.00%
Q1 2023$12,315
-16.1%
11,298
+12.4%
0.00%
Q4 2022$14,670
+33.4%
10,048
-5.0%
0.00%
Q3 2022$11,000
-38.9%
10,5730.0%0.00%
Q2 2022$18,000
-18.2%
10,5730.0%0.00%
Q1 2022$22,000
-78.8%
10,573
+1.7%
0.00%
Q2 2020$104,000
+82.5%
10,401
-50.0%
0.00%
Q1 2020$57,000
+62.9%
20,801
-29.3%
0.00%
Q4 2019$35,000
-10.3%
29,411
+13.7%
0.00%
Q3 2019$39,000
-56.2%
25,865
+16.9%
0.00%
Q2 2019$89,000
-31.5%
22,135
-26.7%
0.00%
Q1 2019$130,000
-1.5%
30,185
+31.8%
0.00%
Q4 2018$132,000
-32.3%
22,906
+59.0%
0.00%
Q3 2018$195,000
+5.4%
14,408
-7.6%
0.00%
Q2 2018$185,000
-34.4%
15,596
-38.0%
0.00%
-100.0%
Q1 2018$282,000
+147.4%
25,140
+47.2%
0.00%
Q4 2017$114,00017,0840.00%
Other shareholders
ADAPTIMMUNE THERAPEUTICS PLC shareholders Q3 2022
NameSharesValueWeighting ↓
Syncona Portfolio Ltd 1,377,294$2,341,0003.33%
Matrix Capital Management Company, LP 38,974,185$66,256,0001.50%
NEA Management Company, LLC 17,082,612$29,040,0001.49%
Endurant Capital Management LP 1,824,065$3,101,0001.09%
Long Focus Capital Management, LLC 4,679,491$7,955,0000.83%
Key Client Fiduciary Advisors, LLC 416,166$707,0000.69%
PFM Health Sciences, LP 9,109,780$15,487,0000.59%
ACT CAPITAL MANAGEMENT, LLC 90,000$153,0000.21%
DAFNA Capital Management LLC 351,064$597,0000.16%
Rock Springs Capital Management LP 2,357,544$4,008,0000.12%
View complete list of ADAPTIMMUNE THERAPEUTICS PLC shareholders